Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Lucid-MS, allowing the company to proceed directly into a Phase 2 clinical trial for multiple sclerosis. The clearance marks a significant step for the micro-cap biotech, as most drug candidates never reach this stage. The news was highlighted in a NetworkNewsAudio press release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” and the full press release can be viewed at https://nnw.fm/E5nJp.
The approximately 15,000-page IND submission included comprehensive pharmacology, toxicology, and manufacturing data. With the clearance, Quantum BioPharma will initiate a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate Lucid-MS in people with multiple sclerosis. Lucid-MS is a patented new chemical entity that has demonstrated in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. This mechanism-targeting approach distinguishes Lucid-MS from existing therapies that primarily manage symptoms rather than address the root cause of the disease.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is dedicated to the research and development of Lucid-MS. The company also invented UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake as of March 31, 2026. The agreement includes royalty payments of 7% of sales until payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The FDA clearance of the IND is a critical milestone because it allows human testing to begin, moving Lucid-MS closer to potential commercialization. If the Phase 2 trial succeeds, Lucid-MS could become a first-in-class treatment for multiple sclerosis, a chronic disease affecting millions worldwide. The ability to reverse myelin degradation could potentially restore function and improve quality of life for patients. For Quantum BioPharma, this milestone validates its research and development efforts and could attract further investment or partnerships.
Investors and stakeholders can find the latest news and updates relating to QNTM in the company’s newsroom at https://nnw.fm/QNTM. NetworkNewsWire, a specialized communications platform, disseminated the audio press release. More information about NetworkNewsWire is available at https://www.NetworkNewsWire.com, and full terms of use and disclaimers can be found at https://www.NetworkNewsWire.com/Disclaimer.
